Shares of Bionano Genomics (BNGO) are soaring 5.90% in pre-market trading on Tuesday, following a significant upgrade from Maxim Group. The investment firm raised its rating on BNGO from Hold to Buy, setting an ambitious price target of $8 per share.
Maxim analyst Jason McCarthy cited several positive steps taken by the company as the reason for the upgrade. This vote of confidence from a respected Wall Street firm appears to be driving investor enthusiasm, pushing the stock higher before the market opens.
The upgrade aligns with the broader analyst sentiment on Bionano Genomics. According to data from FactSet, the stock currently has an average rating of overweight among analysts, with a mean price target of $7. This collective bullish outlook suggests that Wall Street sees substantial upside potential for BNGO, which is likely contributing to today's pre-market rally.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。